Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.57 |
| ▸ | RARG | P13631 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183090 | 0.84 | FFAR1 (0.55) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL6963261 | 0.81 | PPARG (0.59) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL15348621 | 0.81 | PPARG (0.79) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL5399580 | 0.80 | FFAR1 (0.61) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL4744682 | 0.79 | PPARG (0.83) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL6987933 | 0.79 | FFAR1 (0.49) | PPARGFFAR1RARGRXRAPPARA | |
| SCHEMBL5399098 | 0.78 | FFAR1 (0.59) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL6184172 | 0.78 | FFAR1 (0.59) | PPARGFFAR1RARGRXRAMPC2 | |
| SCHEMBL6183905 | 0.78 | FFAR1 (0.59) | PPARGFFAR1RARGRXRA | |
| Rosiglitazone SCHEMBL2355017 | 0.78 | PPARG (1.00) | PPARGFFAR1RARGRXRAPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | claimed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | claimed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | claimed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | claimed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | PPARG 1/4885FFAR1 6/4885RARG 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.